Pharsight

Firmagon patents expiration

FIRMAGON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9579359 FERRING Method of treating prostate cancer with GnRH antagonist
Feb, 2029

(5 years from now)

US10973870 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(5 years from now)

US10729739 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(5 years from now)

US9415085 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(8 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(8 years from now)

Firmagon is owned by Ferring.

Firmagon contains Degarelix Acetate.

Firmagon has a total of 5 drug patents out of which 0 drug patents have expired.

Firmagon was authorised for market use on 24 December, 2008.

Firmagon is available in powder;subcutaneous dosage forms.

Firmagon can be used as treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect, method of treating prostate cancer.

The generics of Firmagon are possible to be released after 27 April, 2032.

Drugs and Companies using DEGARELIX ACETATE ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of FIRMAGON before it's drug patent expiration?
More Information on Dosage

FIRMAGON family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic